Revolution Medicines has reported positive Phase 3 data for its cancer drug daraxonrasib in metastatic pancreatic cancer, with the results featured at the 2026 ASCO Annual Meeting. Patients receiving the drug achieved a median overall survival of 13.2 months, compared with 6.7 months for those on chemotherapy.
The study met its primary endpoint, and the data could support future regulatory submissions. The results also highlight the growing momentum behind RAS-targeted therapies, one of the most important areas in oncology today.